期刊文献+

分子靶向药物与肿瘤 被引量:2

Molecular Targeted Drugs and Tumors
下载PDF
导出
摘要 依据已知肿瘤发生中涉及的异常分子或基因,设计针对这些特定分子和基因靶点的药物,选择性杀伤肿瘤细胞,这种治疗方法称为肿瘤的分子靶向治疗。目前分子靶向药物用于治疗乳腺癌、非小细胞肺癌、结直肠癌以及淋巴瘤、白血病等恶性肿瘤已取得令人瞩目的疗效。针对现有的治疗恶性肿瘤的分子靶向药物的作一综述。 According to the abnormal molecules or genes involved in the occurrence of the tumor, the drugs targeting these specific molecules and gene targets are designed, which are targeted to the tumor cells. This method of treatment is known as the molecular targeted therapy of tumor. At present, molecular targeted agents are used to treat breast cancer, non-small cell lung cancer, colorectal cancer, lymphoma, leukemia and other malignant tumors. The curative effect of these malignant tumors has been improved significantly. Molecular targeted agents for the treatment of malignant tumors will be described in this review.
出处 《世界肿瘤研究》 2015年第4期65-73,共9页 World Journal of Cancer Research
  • 相关文献

参考文献8

二级参考文献105

  • 1贺其图,时风桐,袁祖正.包头市白血病流行病学调查[J].内蒙古医学杂志,1993,13(2):3-5. 被引量:10
  • 2江倩,陈珊珊,江滨,江浩,丘镜滢,刘艳荣,张艳,秦亚溱,陆颖,黄晓军,陆道培.甲磺酸伊马替尼治疗慢性粒细胞白血病慢性期100例追踪观察[J].中华血液学杂志,2006,27(11):721-726. 被引量:39
  • 3North American Association of Central Cancer Registries (2007) North American age-specific invasive cancer incidence rates, chronic myeloid leukemia,2000-2004, http ://www. cancer-rates, info/ naaccr/.
  • 4Laneuville P, Barnett M J, Belanger R, et al. Recommendations of the Canadian consensus group on the management of chronic myeloid leukemia. Curr Oncol,2006,13:201-221.
  • 5O ' Brien SG, Guilhot F, Goldman JM, et al. International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival ,low rate of transformation and increased rate of major molecular response(MMR) in patients with newly diagnosed chronic myeloid leukemia in chronic phase(CML-CP) treated with imatinib(IM). Blood ,2008,112 : 186a.
  • 6Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable [ J ]. Blood, 2005, 111 ( 5 ) : 2505-2515.
  • 7Sanz MA, Tallman MS. Practice points, consensus, and controversial issues in the management of patients with newly diagnosed acute promyelocytic leukemia [ J ]. Oncologist, 2005, 10(10) :806-814.
  • 8Taliman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia [ J ]. N Engl J Med, 1997, 337(15) :1021-1028.
  • 9Melnick A, Licht JD. Deconstructing a disease: RARer, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia [ J ]. Blood, 1999, 93 ( 10 ) : 3167- 3215.
  • 10Shen Z, Shi Z, Fang J, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia [ J ]. Proc Natl Acad Sci USA, 2004, 101 ( 15 ) :5328-5335.

共引文献69

同被引文献36

引证文献2

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部